Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02402023 · ClinicalTrials.gov registry record · NA

Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery

A NA study of Smoking Cessation, sponsored by Yale University.

Completed
Registry status
NA
Development phase
40
Enrollment target
2
Study locations

NCT02402023 is a NA study of Smoking Cessation that has completed, run by Yale University. The registered enrollment target is 40 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02402023, a NA study of Smoking Cessation, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this clinical trial is to determine the feasibility and efficacy of an intervention designed to increase rates of tobacco abstinence for cancer patients before their cancer surgery.

Conditions Studied

Interventions

  • BEHAVIORAL Contingency Management (CM)
  • BEHAVIORAL Standard of Care (SC)

Study Locations (2)

Connecticut

  • Yale Cancer Center - New Haven

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2014-10
Est. Completion 2017-09
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02402023

The ClinicalTrials.gov registry entry for NCT02402023 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (92% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Contingency Management (CM) is the first listed.

NCT02402023 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, South Carolina.

Frequently Asked Questions

What is clinical trial NCT02402023 about?

NCT02402023 is a clinical study titled "Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery". The purpose of this clinical trial is to determine the feasibility and efficacy of an intervention designed to increase rates of tobacco abstinence for cancer patients before their cancer surgery.

What is the current status of trial NCT02402023?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2014-10. Estimated completion is 2017-09.

What conditions does trial NCT02402023 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT02402023?

The interventions under investigation include: Contingency Management (CM) (BEHAVIORAL), Standard of Care (SC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02402023?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02402023 being conducted?

This trial has 2 study locations across Connecticut, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.